Sixth International Symposium on Hormonal Oncogenesis

描述（由申请人提供）：第六届激素肿瘤发生国际研讨会（ISHO）的主要目标是促进对类固醇和肽激素的作用的理解，以及参与介导下游分子靶标的生长因子，这些分子靶标影响内分泌相关靶组织中细胞的发生、繁殖和进展。激素相关的癌症约占女性（乳腺癌）和男性（前列腺）所有癌症的30%。此外，越来越多的证据表明，激素可以影响通常不被认为与内分泌有重大关系的癌症的进展。为了实现这一目标，即将到来的ISHO的突出特点是多学科和翻译。来自不同科学和临床背景的演讲者和与会者将聚集在一起，他们对激素相关癌症有共同的兴趣，他们的最终目标是通过增加我们对细胞和分子过程的理解来改进预防和治疗策略，这些过程强调了激素在癌症发展中的作用。该方案的目的是确定恶性表型的发展，并在新的分子靶标上实施特定药物的使用，以预防癌症的发展以及治疗原发性和复发性疾病。这个ISHO的目的是在激素肿瘤发生领域提供癌症研究的前沿进展，重点是转化研究。建议举行下列会议：

DESCRIPTION (provided by applicant): The primary goal of the 6th INTERNATIONAL SYMPOSIUM ON HORMONAL ONCOGENESIS (ISHO) is to promote an understanding of the role of steroid and peptide hormones, as well as, growth factors involved in mediating the downstream molecular targets that effect the onset, propagation, and progression of cells contained within endocrine-associated target tissues to malignancy. Hormonally associated cancers comprise ~30% of all cancers occurring in women (breast) and in men (prostate). Moreover, there is growing evidence that hormones can affect the progression of cancers that are not normally considered to be under significant endocrine involvement. To attain this goal, the salient characteristics of the upcoming ISHO are multi-disciplinary and translational. An assembly of speakers and attendees of different scientific and clinical backgrounds will be gathered with a common interest in hormonally-related cancer whose ultimate goal is to improve both preventive and treatment strategies by increasing our understanding of the cellular and molecular processes which underline its progress and the role that hormones play in cancer development. The program aim is to identify the development of a malignant phenotype and implement the use of specific agents on novel molecular targets to prevent cancer development and in the treatment of primary and recurrent disease. The intent of this ISHO is to provide cutting edge progress in cancer research in the field of hormonal oncogenesis with an emphasis in translational research studies. The following sessions are proposed: SESSION I. Stem/Progenitor Cells. SESSION II. Targeting Early Pre-invasive Hormonal Cancers. SESSION III. Deregulation of Mitosis. SESSION IV. New Diagnostic and Prognostic Markers for Hormonal Cancer Risk. SESSION V. Microenvironment in Neoplasia. SESSION VI. Novel Paradigms and Therapies in Hormonal Cancers. Additionally, there will be one PLENARY and three STATE OF THE ART lectures, as well as two Poster Sessions, of which a limited number of oral presentations will be scheduled to be discussed by all attendees. The proceedings of the ISHO will be published in a book from Springer, New York, as has been the case of all past symposia. The diversity of the disciplines presented by speakers, the attendee's discussions, and the intimate nature because of size and structure of these symposia have uniquely fostered subsequent collaborations among different investigators that normally would not come together in other scientific meetings, thus greatly accelerating finding solutions for these important cancers.